Castle Creek Biosciences

Castle Creek Biosciences, Inc. is a clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients with rare diseases who lack available treatment options. The company’s most advanced candidate product, dabocemagene autoficel (FCX-007, D-Fi), is currently being evaluated in a Phase 3 clinical trial for the localized treatment of chronic wounds caused by recessive dystrophic epidermolysis bullosa (RDEB). The company is also currently evaluating FCX-013 in a Phase 1/2 clinical trial for the treatment of moderate to severe localized scleroderma.